LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the Company’s
… diseases, announced today that its sepofarsen (QR-110) drug candidate, which is being developed for targeting the … the PRIME program provides a framework for enhancing our development plans by working closely with the EMA.” The EMA … the risks and uncertainties inherently associated with drugdevelopment, including that any one or more of our …
… Robert Friesen to Senior Vice President Science and Early Development. David M. Rodman, M.D., Chief Development … in March 2017 with extensive experience in rare disease drugdevelopment, translational medicine and RNA …
… ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan … are no therapies commercially available or in clinical development for the vision loss associated with this disease. … oligonucleotide drug discovery platform with accelerated drugdevelopment strategies for rare diseases. Orphan drug …
… Advisory Board that will play a strategic role in the development of the Company’s pipeline. The Scientific … Levin PhD , has more than two decades of experience in RNA drugdevelopment from discovery through drug registration, …
… delivery data, and an update on preparation for clinical development to be provided for QR-313. M. Peter Marinkovich, … Boer. “The invention and patenting of Axiomer® can drive drug discovery and development of a new class of … Board. Dr. Levin has three decades of experience in RNA drugdevelopment from discovery through drug registration, …